Leerink Partners upgraded shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) from a market perform rating to an outperform rating in a research report report published on Wednesday, MarketBeat ...
Research analysts at Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for shares of Maze Therapeutics in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback